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Abstract
Background: Hepatitis C Virus (HCV) is a significant public health burden and small animal models
are needed to study the pathology and immunobiology of the virus. In effort to develop
experimental HCV mouse models, we screened a panel of HCV replicons to identify clones capable
of replicating in mouse hepatocytes.
Results:  We report the establishment of stable HCV replication in mouse hepatocyte and
fibroblast cell lines using replicons derived from the JFH-1 genotype 2a consensus sequence. Viral
RNA replication efficiency in mouse cells was comparable to that observed in human Huh-7
replicon cells, with negative-strand HCV RNA and the viral NS5A protein being readily detected
by Northern and Western Blot analysis, respectively. Although HCV replication was established in
the absence of adaptive mutations that might otherwise compromise the in vitro infectivity of the
JFH-1 clone, no infectious virus was detected when the culture medium from full length HCV RNA
replicating mouse cells was titrated on Huh-7 cells, suggesting that the mouse cells were unable to
support production of infectious progeny viral particles. Consistent with an additional block in viral
entry, infectious JFH-1 particles produced in Huh-7 cells were not able to establish detectable HCV
RNA replication in naïve mouse cells.
Conclusion: Thus, this report expands the repertoire of HCV replication systems and possibly
represents a step toward developing mouse models of HCV replication, but it also highlights that
other species restrictions might continue to make the development of a purely murine HCV
infectious model challenging.
Background
Hepatitis C virus (HCV) is an enveloped, positive-strand
RNA virus that causes acute and chronic hepatitis [1].
Between 70–90% of those who become infected fail to
clear the virus and remain chronically infected with the
risk of developing liver cirrhosis and hepatocellular carci-
noma [2]. Unfortunately, there is no vaccine available to
prevent this infection, and the only approved treatment
has toxic side effects and is only effective in a subset of
patients [3,4].
Even though recent work has led to the development of in
vitro HCV infection systems, which allow for molecular
analysis of the entire viral life cycle [5-7], the study of the
immunobiology and pathogenesis of HCV still requires
the development of genetically defined small animal
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models. One obstacle to the development of HCV mouse
models has been the limited host range of the virus. The
restrictions that block HCV infection in mice are not well
defined, but appear to involve multiple steps such as viral
entry and genome replication.
Notably however, HCV replicons based on engineered
viral genomes into which the antibiotic resistant marker
neomycin phosphotransferase (neo) has been inserted
[8](Fig. 1A) provide a means of experimentally by-passing
viral entry and actively selecting for HCV replication after
transfection of RNA into cells. The ability to select for cells
replicating the neo-expressing replicon RNA led to the dis-
covery that efficient replication of most HCV replicons in
cell culture requires adaptive mutations in the viral
genome [9-13]. Although HCV replication initially could
only be achieved in the human hepatoma cell line, Huh-
7, the ability to select for replication enhancing mutations
eventually led to the establishment of HCV replication in
other hepatic (HepG2 and IMY-N9 [14]) and nonhepatic
(HeLa [15,16] and HEK293 [15,17]) human cell lines.
Unlike other published studies that focus exclusively on
HCV replication in human and/or primate cell lines, Zhu
et al (2003) further demonstrated that replication of the
HCV-N genotype 1b subgenomic replicon could be initi-
ated in one of the several mouse cell lines tested. How-
ever, this replication could only be established in a single
mouse cell line after transfection of total RNA extracted
from HeLa cells that were already replicating the adapted
replicon (i.e. total human cellular RNA presumably con-
taining a quasispecies of HCV replicons)[16]. In contrast,
HCV replication could not be initiated in these mouse
cells by transfection of in vitro transcribed replicon RNA
generated from either the parental replicon construct or
from any of the "adapted" replicon clones isolated from
their original mouse replicon cells. Hence, no "mouse-
permissive" HCV replicon clone was identified.
Because the development of HCV mouse models would
be greatly facilitated by the identification of defined HCV
clone(s) capable of establishing and maintaining replica-
tion in mice, we assembled a panel of HCV replicons
derived from different HCV genotypes and assessed their
ability to replicate in mouse cells. We show that JFH-1
genotype 2a subgenomic and full length replicons are able
to stably replicate in multiple mouse hepatocyte and
fibroblast cell lines following transfection of the replicon
RNA. Although the HCV replication achieved in mouse
hepatocytes was not dependent on adaptive mutations
that might compromise the infectivity of the viral clone,
no infectious HCV was detected in the media of mouse
cells replicating full length HCV RNAs, nor were infec-
tious JFH-1 virus particles produced in Huh-7 cells able to
infect naïve mouse cells. Thus, these mouse cells are per-
missive for JFH-1 HCV replication, but exhibit blocks in
both viral entry and production of infectious particles.
Results
Establishment of G418-resistant mouse hepatocyte 
colonies after transfection of subgenomic replicons 
encoding the neomycin selection gene
Because different HCV replicon clones exhibit a range of
replication efficiencies in Huh-7 cells, we hypothesized
that different replicons might also display differences in
their ability to replicate in mouse cells. Thus, we screened
a panel of subgenomic HCV replicons derived from geno-
types 1b, 1a, and 2a for their ability to confer G418 resist-
ance to mouse hepatocytes in vitro. We initially screened
for HCV replication in immortalized Met Mouse Hepato-
cytes (MMH) cells; however, because HCV replication effi-
ciency within different Huh-7 cell lines can vary, we tested
(A) Schematic diagram of HCV genomic and replicon RNA Figure 1
(A) Schematic diagram of HCV genomic and replicon RNA. (B) Representative crystal violet staining of G418-resistant colony 
formation in MMHD3 mouse hepatocytes after transfection with sgJFH-1 HCV RNA. Notably, although MMH cells exhibit rel-
atively low transfection efficiency, numerous G418-resistant colonies form following transfection of HCV replicon RNA.Virology Journal 2006, 3:89 http://www.virologyj.com/content/3/1/89
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HCV replication in two independently derived MMH cell
lines, MMHD3 [18] and MMH1-1 [19].
Replicon RNA from the clones listed in Table 1 was tran-
scribed in vitro and electroporated into MMH cells. Trans-
fected cells were then treated with 500 μg/ml G418, which
was the minimal concentration required to effectively kill
untransfected control cell cultures. Despite the fact that
G418-resistent Huh-7 cell colonies survived the selection
process after transfection with all of the replicon RNAs
tested, RNA transcribed from the HCV genotype 1b clones
(Con1 and HCV-N) and the HCV genotype 1a H77 clone
did not generate G418-resistent mouse cell colonies (data
not shown). In contrast, transfection of genotype 2a sub-
genomic (sg) JFH-1 RNA produce G418-resistant mouse
hepatocyte colonies in both MMH cell lines in multiple
independent transfection experiments (Fig. 1B).
Expression and replication of sgJFH-1 HCV replicons in 
immortalized mouse hepatocytes
To confirm the expression and replication of HCV in
MMHD3 and MMH1-1 cells, G418-resistant cell colonies
were expanded for further analysis. Western Blot analysis
of total cell lysate verified that the viral NS5A protein was
present in each of the MMHD3 and MMH1-1 replicon cell
clones (Fig. 2A, lanes 5, and 6–11, respectively). Yet, con-
stitutive HCV protein expression was not due the integra-
tion of an HCV transgene, as PCR analysis on cellular
genomic DNA revealed no evidence of JFH-1 sequences
(data not shown).
Clones were also examined for the presence of HCV RNA
by strand-specific Northern Blot. Positive-strand (Fig. 2B,
top panel) and negative-strand (Fig. 2B, middle panel)
HCV RNA was detected not only in Huh-7 control cell
clones (Fig. 2B, lanes 11–15), but also in the mouse
clones derived from MMHD3 and MMH1-1 cells (Fig. 2B,
lanes 2 and 4–9, respectively). Although the signal inten-
sity observed with these independently labeled and
hybridized riboprobes can not be compared to determine
the ratio of positive-strand to negative-strand HCV RNA,
both probes demonstrated stringent strand-specific
hybridization when incubated with membranes contain-
ing serial dilutions (109, 108, and 107 copies) of in vitro
transcribed positive-strand (Fig. 2B, lanes 16–18) and
negative-strand (Fig. 2B, lanes 19–21) sgJFH-1 RNA con-
trols, clearly demonstrating that negative-strand HCV
RNA replication intermediates were being produced in the
clones.
RT-QPCR analysis of the same RNA samples indicated
that HCV RNA levels among the mouse sgJFH-1 replicon
clones ranged from 2.9 × 106 – 7.0 × 107 copies per micro-
gram (copies/μg) of total cellular RNA. This was similar to
the 7.4 × 106 – 8.5 × 107 copies/μg observed in the human
sgJFH-1 replicon clones. Thus, the average 2.0 × 107 HCV
RNA copies/μg calculated in the mouse cells was compa-
rable to the average 5.0 × 107  HCV RNA copies/μg
detected in the Huh-7 clones indicating that while the
level of the HCV RNA does vary between individual cells
clones, no statistical difference in RNA level was detecta-
ble between mouse and human cells.
Adaptive mutations are not required for replication of 
sgJFH-1 replicons in mouse hepatocytes
Because adaptive mutations are required for efficient rep-
lication of many HCV replicons in cell culture [9-11,20-
22], we sequenced replicon clones obtained from our
mouse cell lines to determine whether the population of
sgJFH-1 replicons present in the MMH cells had acquired
any adaptive mutations. RNA was extracted from 3 of the
MMH replicon cell lines (MMHD3-sgJFH#1 and MMH1-
1sgJFH#4 and #9). After reverse transcription, 4 PCR
primer sets were used to amplify overlapping segments
spanning the sgJFH-1 cDNA (Fig. 3A). These PCR prod-
ucts were ligated into the pGEMT-Easy vector and 12 indi-
vidual clones of each fragment were sequenced. Although
random mutations were observed throughout the cloned
genomes, none of the changes were detected in more than
1 of the 12 clones sequenced (Fig. 3B), supporting the
conclusion that adaptive mutations had not become
established in the mouse replicon population. Also con-
sistent with the absence of replicon adaptive mutations,
total RNA isolated from both MMH and Huh-7 replicon
cells containing comparable copies of sgJFH RNA (as
determined by RT-QPCR) formed equivalent numbers of
G418-resistant colonies/μg of viral RNA when re-trans-
fected into naïve MMH cells (data not shown).
To determine if the initial establishment of the mouse rep-
licon clones had selected for adapted MMH cells that were
more permissive for HCV replication, we also "cured" the
sgJFH-1 replicon from our MMH replicon cells with a 3
week treatment of IFNα (1000 U/ml) and IFNγ (500 U/
ml), but subsequent sgJFH-1 RNA transfections into these
"cured" (e.g. G418-sensitive, HCV-negative) mouse cells
did not produce higher numbers of G418-resistent colo-
nies/μg of input RNA compared to parallel transfections
into the parental MMH cell lines indicating that we had
Table 1: HCV Replicons Screened
Genotype Clone
1b sgCon1 WT
1b sgCon1 S1179I
1b sgHCV-N
1a sgH77
2a sgJFH-1
sg = subgenomicVirology Journal 2006, 3:89 http://www.virologyj.com/content/3/1/89
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not selected MMH cells that more efficiently allow for
establishment of HCV replication (data not shown).
Replication of sgJFH-1 HCV in other mouse cell lines
Because the sgJFH-1 replicon was able to replicate in
MMH cells without any apparent viral or cellular adaptive
mutations, we proceeded to determine if this ability was
restricted to MMH cells or if the JFH-1 clone could repli-
cate in other mouse cell lines. Hence, we transfected in
vitro transcribed sgJFH-1 RNA into mouse AML12 hepato-
cytes as well as mouse NIH3T3 embryonic fibroblasts and
selected for cells that were able to support replication of
the neo-expressing replicon. Figure 4A shows strand-spe-
cific HCV Northern Blot analysis that verifies the presence
of both positive-strand (Fig. 4A, top panel) and negative-
strand (Fig. 4A, middle panel) HCV RNA in all the AML12
mouse hepatocyte cell clones. Similarly, negative strand-
specific HCV Northern Blot analysis of total RNA from 9
NIH3T3 replicon cell clones also confirmed the presence
of negative-strand HCV RNA in these non-hepatic mouse
cells demonstrating that the sgJFH-1 HCV clone can repli-
cate in a variety of mouse cell lines (Fig. 4B).
Replication of full length JFH-1 HCV replicons in mouse 
cells
To determine if full length HCV replication also could be
established in mouse cells, in vitro transcribed full length
(fl) JFH-1 replicon RNA was electroporated into MMH1-1
and Huh-7 cells, and cells supporting replicon replication
were selected with 500 μg/ml G418. Northern Blot analy-
sis of total RNA isolated from the resulting G418-resistant
clones confirmed that negative-strand flJFH-1 RNA was
present in both MMH1-1 (Fig. 5, lanes 1–4) and Huh-7
(Fig. 5, lanes 5–10) transfected cultures. However, unlike
sgJFH replicon clones in which HCV RNA levels were
equivalent between human and mouse cells clones, RT-
QPCR analysis indicated that HCV RNA levels were
approximately 3-fold lower in flJFH-1 MMH1-1 cell
clones (9.5 × 104 – 7 × 105 copies/μg total RNA) compared
to flJFH-1 Huh7 cell clones (3.1 × 105 – 1.9 × 106 copies/
μg total RNA).
Lack of infectious HCV particle entry into and secretion 
from mouse hepatocytes
Because the flJFH-1 is capable of producing infectious
HCV particles, we proceeded to determine whether the
MMH1-1 mouse cells were able to secrete infectious HCV
particles and/or were permissive for flJFH-1 entry. To
determine if the flJFH-1 replicon clones were secreting
infectious HCV particles that could transmit G418-resist-
ance, the culture media from individual clones was col-
lected and used to inoculate naive Huh-7 and MMH1-1
cells. Although G418-resistant colonies formed when
Huh-7 cells were inoculated with the supernatant from
Huh-7 flJFH-1 replicon cells, the culture supernatant from
MMH1-1 flJFH-1 replicon cells did not confer G418-
resistance to Huh-7 cells suggesting that the mouse cells
were not able to secrete infectious HCV particles. Titration
of the same media on Huh-7 cells further confirmed that
all the Huh-7 flJFH-1 cell clones were secreting infectious
HCV particles (expressed as foci forming units per ml),
while no infectious HCV was detected in the media from
MMH1-1 flJFH-1 cells, even after 50-fold concentration
by centrifugal filtration (Fig. 5B).
Notably, inoculation of naïve MMH1-1 cells with media
from either Huh-7 flJFH-1 or MMH1-1 flJFH-1 cell cul-
tures did not confer G418-resistence to the mouse cells
confirming that HCV particles are unable to enter mouse
cells. Importantly, inoculation with high titer authentic
HCV protein and RNA detection in immortalized mouse hepatocytes Figure 2
HCV protein and RNA detection in immortalized mouse hepatocytes. (A) Western Blot detection of HCV NS5A. Cell lysate 
was harvested from individual cell clones and resolved by SDS-PAGE. Samples include cell lysate from Huh-7 sgCon1 (lane 1); 
non-transfeted (NT) Huh-7 (lane 2); Huh-7 sgJFH-#2 (lane 3); NT MMHD3 cells (lane 4); MMHD3 sgJFH#1 (lane 5); and 
MMH1-1sgJFH#4, 5, 6, 7, 9, and 10 (lanes 6–11). (B) Northern Blot detection of sgJFH-1 RNA. Total RNA was isolated from 
non-transfected (NT) and individual MMHD3 (lanes 2), MMH1-1 (lanes 4–9), and Huh-7 (lanes 11–15) sgJFH-1 replicon clones. 
Positive-strand (top panel) and negative-strand (middle panel) HCV RNA was detected with 32P-labeled strand-specific ribo-
probes. Cellular GAPDH was detected with a 32P-labeled cDNA probe (bottom panel). Serial dilutions of in vitro transcribed 
positive-strand and negative-strand sgJFH-1 RNA (109, 108, 107) are shown in lanes 16–18 and lanes 19–21, respectively.Virology Journal 2006, 3:89 http://www.virologyj.com/content/3/1/89
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HCV virus produced in Huh-7 cells also failed to establish
JFH-1 replication in MMH1-1, AML12, or NIH3T3 mouse
cells (data not shown).
To determine whether the lack of detectable infectivity in
the culture medium of flJFH-1 MMH1-1 replicon clones
was due to an inability to secrete HCV particles or due to
the secretion of non-infectious HCV particles, the culture
supernatant from Huh-flJFH#7 and MMH1-1-flJFH#2
cultures were subjected to sucrose density gradient centrif-
ugation. Fractions were collected, total RNA extracted, and
RT-QPCR analysis performed to determine the amount of
viral RNA in each fraction (Fig. 5C). HCV RNA in the
supernatant of the Huh-flJFH#7 cells was detected over a
broad density range of 1–1.15 g/ml, with a predominant
peak at 1.07 g/ml, supporting the conclusion that the viral
RNA was associated with enveloped particles (Fig. 5C).
This is similar to the HCV RNA density profile reported for
in vitro-derived infectious JFH-1 particles from which RNA
was observed in density fractions from 1–1.15 g/ml with
a peak at 1.09–1.10 g/ml [5,6]. In contrast, there was no
specific low density peak of HCV RNA in the media of
MMH1-1flJFH#2 cells and total viral RNA levels in the
supernatant were significantly lower than that seen the in
Huh-7 replicon cell supernatant. Hence, these results sup-
port the conclusion that mouse hepatocytes do not effi-
ciently secrete enveloped, flJFH-1 RNA-containing
particles.
Discussion
In this study, we have shown that replicon clones derived
from the HCV JFH-1 consensus cDNA can establish and
maintain efficient replication in both mouse hepatocytes
(e.g. MMHD3, MMH1-1, AML12) and mouse embryonic
fibroblasts (e.g. NIH3T3). This discovery reveals a previ-
ous unrealized breadth in the host range of the JFH-1 HCV
clone, and expands our ability to develop experimental
HCV model systems. In addition to observing stable
expression of viral proteins and replication of viral RNA
(Fig. 2), we found that HCV replication in mouse hepato-
cytes is not dependent on adaptive mutations in the viral
genome (Fig. 3), but is sensitive to inhibition by interfer-
ons (data not shown) and the HCV-specific small mole-
cule inhibitor, BILN2061 (data not shown). Taken
together, these results demonstrate replication of non-
adapted HCV replicon clones in mouse cells, and they
potentially provide the basis for the production of a
mouse model of HCV replication.
While Zhu et al., (2003) previously provided evidence
that HCV replication in mouse hepatocytes was possible,
the data presented here differs from that report in three
fundamental ways. First, Zhu et al., (2003) could only ini-
tiate HCV replication in mouse cells by transfection with
a HCV RNA quasispecies obtained from previously estab-
lished HeLa replicon cells, but they were not able to estab-
lish replication in mouse cells with any individual
replicon clone. In contrast, we have been able to identify
a defined HCV replicon clone capable of replicating in
various mouse cell lines. The identification of a specific
mouse-permissive HCV clone is advantageous because it
facilitates mouse model development and allows for
Sequence analysis of sgJFH-1 replicons in mouse hepatocytes Figure 3
Sequence analysis of sgJFH-1 replicons in mouse hepatocytes. 
(A) PCR primer sets used to amplify overlapping HCV DNA 
segments. (B) Twelve clones of each fragment were 
sequenced with an ABI automatic DNA sequencer. Muta-
tions within viral proteins are indicated by the amino acid 
position of the mutation within the context of the full length 
HCV open reading frame. Mutations in the 3' UTR are desig-
nated by their nucleotide position in the context of the full 
length HCV genome.Virology Journal 2006, 3:89 http://www.virologyj.com/content/3/1/89
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reverse-genetics experimentation. Second, whereas repli-
cation of the subgenomic 1b HCV-N replicon reported by
Zhu et al., (2003) was restricted to one specific mouse cell
line, we have been able to establish JFH-1 HCV replication
in multiple mouse cell lines significantly enhancing the
likelihood that future in vitro and in vivo experimental
HCV mouse models based on the JFH-1 clone might be
possible. Finally, while the previous success was depend-
ent on cell culture adaptive mutations that prevent HCV
infectivity [23], we have demonstrated that replicons
derived from the JFH-1 consensus sequence can replicate
in mouse hepatocytes, in the absence of adaptive muta-
tions that might otherwise alter the infectivity of the
clone.
The ability of the JFH-1 clone to replicate efficiently in tis-
sue culture in the absence of adaptive mutations has
recently led to the development of in vitro HCV infection
models in Huh-7 cells [5-7] and the demonstration that
full length HCV replicons are capable of producing infec-
tious viral particles (Fig. 5B–C). Likewise it provided us
the opportunity to study the ability of mouse cells that
support JFH-1 replication to uptake and secrete infectious
HCV JFH-1 particles. Consistent with previous HCV pseu-
doparticles data, we observed no evidence that HCV parti-
cles were able to productively enter mouse cells, even
when we used G418 treatment to select for cells that
might have become HCV positive following inoculation.
More unexpectedly, we also observed that mouse hepato-
cytes replicating infectious JFH-1 RNA were not able to
secrete infectious HCV RNA containing particles. Though
it is possible there were low levels of infectious particles
present that were below the detection limits of our assays,
sucrose density gradient analysis and RT-QPCR analysis of
HCV RNA isolated from the mouse culture supernatants
supports the conclusion that very few, if any, enveloped,
HCV RNA-containing particles were being secreted from
these mouse cells (Fig. 5C). This may reflect an inability to
assemble infectious particles, secrete viral particles, or
both. Hence, in addition to productive viral entry, infec-
Northern Blot detection of sgJFH-1 RNA in AML12 mouse  hepatocytes and NIH3T3 mouse fibroblasts Figure 4
Northern Blot detection of sgJFH-1 RNA in AML12 mouse 
hepatocytes and NIH3T3 mouse fibroblasts. (A) Negative-
strand HCV (top panel), positive-strand HCV (middle panel), 
and cellular GAPDH (bottom panel) was detected by North-
ern Blot analysis of total RNA isolated from non-transfected 
(NT) parental AML12 cells (lane 1) and 8 individual sgJFH-1 
RNA transfected clones (lanes 2–9). In vitro transcribed posi-
tive-strand (lane 10) and negative-strand (lane 11) sgJFH-1 
RNA was included as controls. (B) Northern Blot analysis for 
negative-strand HCV (top panel) and cellular GAPDH (bot-
tom panel) was performed on total RNA isolated from non-
transfected (NT) parental NIH3T3 cells (lane 10) and 9 ran-
domly chosen sgJFH-1 RNA transfected clones (lanes 1–9).
Intracellular and extracellular HCV RNA produced by flJFH-1 mouse replicon clones Figure 5
Intracellular and extracellular HCV RNA produced by flJFH-1 mouse replicon clones. (A) Northern Blot analysis for negative-
strand HCV (top panel) and cellular GAPDH (bottom panel) was performed on total RNA isolated from MMH1-1 replicon 
clones (lanes 1–4), Huh-7 replicon clones (lanes 5–9), and non-transfected (NT) Huh-7 cells (lane 10). (B) HCV infectivity titer 
in the culture medium of the same MMH and Huh-7 clones was determined by incubating serial dilutions on naïve Huh-7 cells 
and performing immunofluorescence for HCV 3 days post-inoculation, as previously described [5]. The titer is expressed as 
NS5A-positive focus-forming units (ffu) per ml of medium. (C) RT-QPCR detection of extracellular HCV RNA following 
sucrose density gradient centrifugation.Virology Journal 2006, 3:89 http://www.virologyj.com/content/3/1/89
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tious particle production appears to be another aspect of
the HCV life cycle that may not be readily recapitulated in
mouse hepatocytes. Clearly, elucidating the basis of this
phenomenon may help us understand the key steps
required for infectious HCV particle secretion in human
cells.
Conclusion
The data presented in this report demonstrate that JFH-1
derived HCV replicon clones can efficiently replicate in
mouse cells. While this discovery certainly represents an
advance in our ability to develop mouse models of HCV
replication, further analysis of infectious JFH-1 HCV entry
into and egress from mouse cells also identified at least 2
other aspects of the HCV life cycle that are not supported
by the mouse hepatocytes tested. Such species restrictions
will likely continue to make the development of a purely
murine HCV infectious model challenging.
Methods
HCV constructs
Constructs containing the non-adapted wild type
(pHCVrep1b BartMan_AvaII) and Huh-7 cell adapted
[pHCVrep1bBB7 (S1179I)] HCV Con1 genotype 1b subg-
enomic replicons [9] and the genotype 1a H77 subge-
nomic replicon [H/SG-Neo(L+I)] [22] were provided by
Dr. Charles Rice (Rockefeller University, NY). The
pNNeo/3-5B(SI) construct encoding the genotype 1b
HCV-N subgenomic replicon was provided by Dr. Stanley
Lemon (University of Texas Medical Branch, Galves-
ton)[13]. The constructs pSGR-JFH1, pFGR-JFH1, and
pJFH-1 containing the sgJFH-1 HCV genotype 2a JFH-1
replicon, the full length (fl)JFH-1 replicon, and the
genomic JFH-1 viral clone have been described [7,24,25].
In all constructs, the HCV cDNA is located at the 1+ posi-
tion 5' of the T7 promoter. Plasmids were linearized at the
3' end of the HCV cDNA and used as a template for in vitro
transcription by T7 RNA polymerase (MEGAscript;
Ambion, Austin, TX). To generate strand-specific RNA
probes, a 1 kb fragment of the JFH-1 NS5B coding region
(HindIII-EcoRV) was cloned into the pBSKII+ vector to
allow for T7 and SP6-driven transcription of JFH-1 nega-
tive and positive strand probes, respectively.
Cell culture
Huh-7 human hepatocytes and NIH3T3 mouse fibrob-
lasts (CRL-1658; ATCC, Manassas, VA) were maintained
in DMEM supplemented with 10% fetal calf serum and
Penicillin-Streptomycin-Glutamine (100×, liquid)(Gibco
Invitrogen Corporation, Carlsbad, CA). AML12 mouse
hepatocytes (ATCC; CRL-2254) were maintained in
DMEM/F12 supplemented with 10% fetal calf serum,
Penicillin-Streptomycin-Glutamine (100×, liquid), insu-
lin-transferrin-selenium (100×, liquid)(Gibco Invitro-
gen), and 40 ng/ml dexamethasone (Sigma, St. Louis,
MO). MMHD3 (Met Murine Hepatocyte) cells were
obtained from Marco Tripodi (Università La Sapienza,
Italy)[18]. This immortalized mouse hepatocyte cell line
was derived from the liver of transgenic mice, which
express the constitutively active cytoplasmic domain of
the human hepatocyte growth factor receptor (cMet) in
their livers. The MMH1-1 cells were independently
derived from double transgenic cMet transgenic mice that
also have a hepatitis B virus (HBV) transgene [19].
Although these cells contain a HBV transgene, expression
and replication of HBV in these cells only occurs after the
cells become confluent and are further differentiated in
the presence of 2% DMSO for 8 days [19]. All of the exper-
iments presented here were performed on subconfluent
cell cultures in the absence of DMSO; therefore, no HBV
replication was occurring in these cells (data not shown).
Both MMHD3 and MMH1-1, were plated on collagen I
Biocoat dishes (Becton Dickinson, Franklin Lakes, NJ) in
RPMI 1640 (Gibco Invitrogen) supplemented with 10%
fetal calf serum (Gibco Invitrogen), 55 ng/ml EGF (Becton
Dickinson), 16 ng/ml IGF-II (Calbiochem, San Diego,
CA), 10 μg/ml insulin (Sigma) and Penicillin-Streptomy-
cin-Glutamine (100×, liquid)(Gibco Invitrogen)[19].
G418 was added to culture media as indicated (Invitro-
gen).
HCV RNA transfection and G418-resistant colony 
formation
In vitro transcribed HCV RNA or total cell RNA was trans-
fected into cells using a modified electroporation protocol
[10]. Trypsinized cells were washed twice with serum-free
medium and resuspended to a final concentration of 1 ×
107 cells/ml. One to ten micrograms of HCV RNA was
then mixed with 0.4 ml of the cells in a 4 mm cuvette. A
Gene Pulser system (BioRad Laboratories, Hercules, CA)
was used to deliver the following single pulses: Huh-7
(0.27 kV, 100 OHMS, 960 μF); Met-based and AML12
cells (0.45 kV, 100 OHMS, 960 μF); NIH3T3 (0.27 kV,
100 OHMS, 960 μF). For the generation of replicon
clones, transfected cultures were maintained in the pres-
ence of G418 at a concentration of 500 μg/ml until all
cells died or distinct G418-resistant cell colonies formed.
To visualize colony formation, cells were fixed and
stained with crystal violet.
RNA analysis
Total cell RNA was isolated by the guanidine thiocyanate
method using standard protocols [26]. RNA was resolved
in 1% agarose, 2.2 M formaldehyde gels and transferred to
nylon membrane (Schleicher & Schuell, Keene, NH).
Membranes were cut across the 28S ribosomal band so
that the top of the blot could be hybridized with 32P-
labeled strand-specific riboprobes (MAXIscript; Ambion),
while the bottom was hybridized with 32P-labeled cellular
GAPDH cDNA probe (Random Prime Synthesis; Invitro-Virology Journal 2006, 3:89 http://www.virologyj.com/content/3/1/89
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gen, Carlsbad, CA). Hybridized probe was visualized
using a storage phosphor system (Cyclone; Packard
Instrument Co.). Alternatively, 1 μg of RNA was DNAse
treated (DNA-free reagent; Ambion) for reverse transcrip-
tion quantitative polymerase chain reaction (RT-QPCR).
RNA was used for cDNA synthesis using the TaqMan
reverse transcription reagents (Applied Biosystems, Foster
City, CA), followed by real-time PCR quantification using
a BioRad iCycler (BioRad Laboratories). HCV and
GAPDH transcript levels were determined relative to a
standard curve comprised of serial dilutions of plasmid
containing the HCV cDNA or the mouse GAPDH gene.
The PCR primers used to detect JFH-1 (GenBank
AB047639) were 5'-TCTGCGGAACCGGTGAGTA-3'
(sense) and 5'-TCAGGCAGTACCACAAGGC-3' (anti-
sense). The PCR primers used to detect H77C (GenBank
AF011751) were 5'-GTCTGCGGAACCGGTGAG-3'
(sense) and 5'-GGCATTGAGCGGGTTTATC-3' (anti-
sense). The PCR primers used to detect both genotype 1b
HCV clones (Genbank AJ242652 and AF139594) were 5'-
ATGGCGTTAGTATGAGTGTC-3' (sense) and 5'-GGCATT-
GAGCGGGTTGATC-3' (antisense). The PCR primers used
to detect mouse GAPDH (GenBank M32599) were 5'-
TCTGGAAAGCTGTGGCGTG-3' (sense) and 5'-CCAGT-
GAGCTTCCCGTTCAG-3' (antisense).
Western Blot analysis
Cells were harvested in RIPA buffer (50 mM Tris-HCl, pH
7.4, 1% NP-40, 0.25% Na-deoxycholate,150 mM NaCl, 1
mM EDTA) supplemented with a protease inhibitor cock-
tail (Roche Applied Science, Indianapolis). Fifty micro-
grams of protein was resolved by SDS-PAGE and
transferred to Hybond nitrocellulose membranes (Amer-
sham Pharmacia, Piscataway, NJ). Membranes were
sequentially blocked with 5% Nonfat Milk, incubated
with a 1:500 dilution of the polyclonal rabbit NS5A anti-
body, M15 (provided by Dr. Michael Houghton, Chiron,
Emeryville, CA), washed 3 times with PBS/0.05%
Tween20, incubated with horseradish peroxidase-conju-
gated goat anti-rabbit antibody (Pierce, Rockford, Illi-
nois), and washed again. Bound antibody complexes were
detected with SuperSignal chemiluminescent substrate
(Pierce).
Sequencing HCV replicons
Total cell RNA was extracted from 3 mouse replicon cell
lines (MMHD3sgJFH#1, MMH1-1sgJFH#4, and MMH1-
1sgJFH#9). Reverse transcription was carried out with ran-
dom hexamers using 1 μg of RNA (Transcriptor Reverse
Transcriptase; RocheApplied Sciences, Indianapolis, IN).
HCV DNA was subsequently amplified with high fidelity
Tgo polymerase (Roche). Four PCR primer sets were used
to amplify overlapping segments spanning positions 22 to
2264, 2002 to 4241, 4007 to 6223, and 6006 to 7975 of
the sgJFH-1 replicon (Fig. 3A). The PCR products were
cloned into the pGEM-T Easy plasmid (Promega, Madison
WI), and 12 clones of each fragment (4 from each cells
line) were sequenced with an ABI automatic DNA
sequencer using the M13 forward and reverse primers in
the vector as well as 20–21 bp sequencing primers located
within the HCV subgenomic replicon at nucleotide posi-
tions: 1252, 1790, 2053, 2290, 2571, 2820, 3269, 3836,
4256, 4634, 4813, 5215, 5425, 6148, 6555, and 7416.
Titration of infectious HCV
Cell supernatants were serially diluted in complete
medium and used to infect naïve MMH and Huh-7 cells
in 96-well plates. The level of HCV infection was deter-
mined 3 days post-infection by immunofluorescence
staining for HCV NS5A as previously described [5]. The
viral titer is expressed as focus-forming units per milliliter
of supernatant (ffu/ml), determined by the number of
NS5A-positive foci detected at the highest HCV-positive
dilution.
Sucrose density gradient analysis
Sucrose density-gradient ultracentrifugation was per-
formed as described [5]. Supernatant from flJFH-1 repli-
con cultures was collected, centrifuged at 4,000 rpm for 5
min to remove cellular debris, and concentrated by cen-
trifugal filteration when indicated (Amicon Ultra; Milli-
pore, Billerica, MA). Samples were loaded onto TNE
buffer (50 mM Tris·HCl, pH 8;100 mM NaCl;1 mM
EDTA)-based 20–60% sucrose gradient and centrifuged at
120,000 × g for 16 h at 4°C using a SW60 rotor in a Beck-
man Coulter L8-80 Ultracentrifuge (Fullerton, CA). Frac-
tions were collected from the bottom of the gradient, and
analyzed for HCV RNA by RT-QPCR.
Note
While this manuscript was being prepared, Chang et al.,
(JVirol. 2006 Aug;80:7364-74) published a report consist-
ent with these data showing that JFH-1 replicons can rep-
licate in mouse embryonic fibroblasts (MEFs).
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